Wenjin Yin

2.2k total citations
90 papers, 1.6k citations indexed

About

Wenjin Yin is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Wenjin Yin has authored 90 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 46 papers in Cancer Research and 29 papers in Molecular Biology. Recurrent topics in Wenjin Yin's work include Breast Cancer Treatment Studies (25 papers), HER2/EGFR in Cancer Research (20 papers) and Cancer-related molecular mechanisms research (12 papers). Wenjin Yin is often cited by papers focused on Breast Cancer Treatment Studies (25 papers), HER2/EGFR in Cancer Research (20 papers) and Cancer-related molecular mechanisms research (12 papers). Wenjin Yin collaborates with scholars based in China, United States and United Kingdom. Wenjin Yin's co-authors include Jinsong Lu, Liheng Zhou, Yueyao Du, Yanping Lin, Yiwei Jiang, Yaohui Wang, Zhenzhou Shen, Jiong Wu, Gen‐Hong Di and Shuguang Xu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Wenjin Yin

82 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wenjin Yin China	23	781	739	647	314	162	90	1.6k
Angel Rodriguez United States	21	494 0.6×	609 0.8×	770 1.2×	235 0.7×	109 0.7×	49	1.4k
Aranzazu Fernández-Martínez Spain	13	517 0.7×	583 0.8×	717 1.1×	281 0.9×	88 0.5×	47	1.5k
Davendra Segara Australia	18	660 0.8×	520 0.7×	585 0.9×	250 0.8×	272 1.7×	27	1.4k
Michaela J. Higgins United States	18	680 0.9×	413 0.6×	530 0.8×	246 0.8×	189 1.2×	60	1.3k
Jinsong Lu China	28	912 1.2×	1.0k 1.4×	829 1.3×	337 1.1×	184 1.1×	95	2.1k
Marc Díez Spain	6	459 0.6×	431 0.6×	510 0.8×	285 0.9×	85 0.5×	15	1.1k
Zhimin Shao China	19	506 0.6×	449 0.6×	409 0.6×	138 0.4×	170 1.0×	96	1.3k
Bárbara Sousa Portugal	19	841 1.1×	493 0.7×	550 0.9×	185 0.6×	139 0.9×	43	1.4k
Jong Han Yu South Korea	22	499 0.6×	576 0.8×	859 1.3×	202 0.6×	105 0.6×	61	1.5k

Countries citing papers authored by Wenjin Yin

Since Specialization

Citations

This map shows the geographic impact of Wenjin Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenjin Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenjin Yin more than expected).

Fields of papers citing papers by Wenjin Yin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenjin Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenjin Yin. The network helps show where Wenjin Yin may publish in the future.

Co-authorship network of co-authors of Wenjin Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Wenjin Yin. A scholar is included among the top collaborators of Wenjin Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenjin Yin. Wenjin Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Liang, et al.. (2025). Metronomic paclitaxel and cisplatin chemotherapy for metastatic breast cancer: insights from a target trial emulation. The Lancet Regional Health - Western Pacific. 55. 101457–101457. 1 indexed citations

Ye, Yumei, et al.. (2025). Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study. Therapeutic Advances in Medical Oncology. 17. 22828964–22828964.

Yin, Wenjin, Tiantian Lu, Xi Yang, et al.. (2024). LMI1, a DUF292 protein family gene, regulates immune responses and cell death in rice. The Crop Journal. 12(6). 1619–1632. 1 indexed citations

Wang, Yaohui, et al.. (2024). Serum lipid ratios as novel prognostic biomarkers for patients with locally advanced breast cancer treated with neoadjuvant therapy. Postgraduate Medicine. 136(5). 541–550.

Yuan, Chenwei, Yaqian Xu, Liheng Zhou, et al.. (2024). Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy in a prospective Chinese cohort. European journal of medical research. 29(1). 454–454. 1 indexed citations

Wang, Yaohui, et al.. (2024). Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer. Annals of Medicine. 56(1). 2409343–2409343.

Qiao, Wen, Cegui Hu, Jiayi Ma, et al.. (2023). Low-dose metronomic chemotherapy triggers oxidized mtDNA sensing inside tumor cells to potentiate CD8+T anti-tumor immunity. Cancer Letters. 573. 216370–216370. 6 indexed citations

Dai, Huijuan, Yanping Lin, Xiaonan Sheng, et al.. (2023). TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer. Journal of Translational Medicine. 21(1). 400–400. 9 indexed citations

Xuan, Wei, Jiaxin Sun, Xiaoqiang Wang, et al.. (2023). The effects of dexmedetomidine on postoperative tumor recurrence and patient survival after breast cancer surgery: a feasibility study. SHILAP Revista de lepidopterología. 1(4). 6 indexed citations

10.

Wan, Caifeng, Liheng Zhou, Ye Jin, et al.. (2023). Strain ultrasonic elastography imaging features of locally advanced breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival. BMC Medical Imaging. 23(1). 216–216. 3 indexed citations

11.

Wan, Caifeng, Liheng Zhou, Hongli Li, et al.. (2023). Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer. Diagnostics. 13(14). 2378–2378. 6 indexed citations

12.

Wu, Yifan, Yaohui Wang, Yaohui Wang, et al.. (2023). Precise diagnosis of breast phyllodes tumors using Raman spectroscopy: Biochemical fingerprint, tumor metabolism and possible mechanism. Analytica Chimica Acta. 1283. 341897–341897. 8 indexed citations

13.

Yin, Wenjin, Yaohui Wang, Ziping Wu, et al.. (2022). Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clinical Cancer Research. 28(17). 3677–3685. 26 indexed citations

14.

Wu, Ziping, Jing Peng, Shuguang Xu, et al.. (2020). Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting. The International Journal of Biological Markers. 35(3). 38–49. 2 indexed citations

15.

Zhang, Shan, Pei-Qi Huang, Huijuan Dai, et al.. (2020). TIMELESS regulates sphingolipid metabolism and tumor cell growth through Sp1/ACER2/S1P axis in ER-positive breast cancer. Cell Death and Disease. 11(10). 892–892. 35 indexed citations

16.

Wu, Ziping, Lei Zhang, Jing Peng, et al.. (2019). Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. Cancer Biology & Therapy. 20(6). 941–947. 16 indexed citations

17.

Zhou, Qiong, Wenjin Yin, Yueyao Du, & Jinsong Lu. (2014). For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures. PLoS ONE. 9(1). e83646–e83646. 18 indexed citations

18.

Jiang, Yiwei, Wenjin Yin, Liheng Zhou, et al.. (2012). First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis. PLoS ONE. 7(3). e32474–e32474. 16 indexed citations

19.

Yin, Wenjin, Yiwei Jiang, Zhenzhou Shen, Zhimin Shao, & Jinsong Lu. (2011). Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials. PLoS ONE. 6(6). e21030–e21030. 120 indexed citations

20.

Lin, Yanping, Wenjin Yin, Tingting Yan, et al.. (2009). Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer. 9(1). 342–342. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact